Abstract
Glutamine (Gln) is a growth determinant in neoplastic tissues. We analysed by RT-PCR the expression of mRNAs coding for the human variants of Gln transporters: ASCT2 (system ASC), SNAT1 [ATA1] (system A), SNAT3 [SN1] and SNAT5 [SN2] (system N), in samples of human malignant gliomas WHO grades III/IV (anaplastic astrocytoma and glioblastoma), glioma-derived cell cultures, brain metastases from peripheral organs, and control brain tissue. SNAT3 mRNA showed a 3-5 times stronger expression in gliomas than in metastases or control tissue, and was virtually absent from glioma cultures. Native glioblastoma immunostained positively with anti-SNAT3 antibody. The expression of ASCT2 mRNA, but not SNAT5 or SNAT1 mRNAs, was increased in all neoplastic tissues studied. Hence, increased expression of SNAT3 is a marker of primary malignant gliomas in situ.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Transport System A / genetics
-
Amino Acid Transport System ASC / genetics
-
Amino Acid Transport Systems, Neutral / genetics
-
Amino Acid Transport Systems, Neutral / metabolism*
-
Biomarkers, Tumor / metabolism*
-
Brain Neoplasms / diagnosis*
-
Brain Neoplasms / metabolism
-
Brain Neoplasms / pathology
-
Glioma / diagnosis*
-
Glioma / metabolism
-
Glioma / pathology
-
Humans
-
Immunohistochemistry
-
Minor Histocompatibility Antigens
-
Predictive Value of Tests
-
RNA, Messenger / metabolism
-
Reproducibility of Results
-
Tumor Cells, Cultured
-
Up-Regulation / physiology
Substances
-
Amino Acid Transport System A
-
Amino Acid Transport System ASC
-
Amino Acid Transport Systems, Neutral
-
Biomarkers, Tumor
-
Minor Histocompatibility Antigens
-
RNA, Messenger
-
SLC1A5 protein, human
-
SLC38A1 protein, human
-
SLC38A5 protein, human
-
system N protein 1